에스티팜

237690KOSDAQ의약품 제조업

62.8 / 100

Reference Date: 2026-07-24

Financial Score21.5 / 40

News Sentiment21.3 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average but PER raises overvaluation concerns. Slightly down 2.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

ESTEPAF, originally established as Samcheonri Pharmaceutical in 1983 and later acquired by Dong-A Ssosiogroup in 2010, has expanded into the oligonucleotide CDMO sector, achieving global top 3 production capacity. It entered the mRNA business in 2020, completed the second oligo facility in 2025, and is advancing clinical trials for its self-developed drugs STP0404 (HIV treatment) and STP1002 (cancer treatment). The company has integrated CRO and CDMO services into a one-stop system, enhancing its pharmaceutical development capabilities through global partnerships.

Number of Employees

1,560people

Average Salary

68.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

43.57Industry Average 11.230.0Point

3.9x industry avg (risky)

PBR

4.15Industry Average 0.810.0Point

5.1x industry avg (risky)

ROE

9.96Industry Average 4.017.0Point

2.5x industry avg (excellent)

Debt Ratio

4.18Industry Average 12.436.5Point

Half of industry avg (excellent)

Trend 2023~20258.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲8.6% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲40.5% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 7.4% (improving, 3yr)

Detailed News Sentiment

13 totalPositive 13Neutral 0Negative 0Average Sentiment Score 85

Positive
사업영역 넓힌 에스티팜…수주잔고 5300억 돌파
에스티팜의 수주잔고가 5000억원을 돌파하며 신규 계약으로 사업 확장과 시너지 효과 기대.
Positive
"경쟁자가 없다?" 동아CDMO 에스티팜, 수주 이어지나…생산시설 실사...
에스티팜의 실적 개선 전망과 추가 수주 기대감으로 긍정적인 시장 반응 예상.
Positive
에스티팜 HIV 신약, 임상 PoC 확보…기술이전 시험대
에스티팜의 HIV 신약이 임상 PoC에서 높은 바이러스 감소 효과를 보여주며 새로운 기전을 입증, 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position5.0Point

52w mid range (40%)

Current 117,900Won52-week high 168,70052-week low 82,700

1-month return2.0Point

1m -2.56% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral기업설명회(IR)개최2026-07-23
Neutral결산실적공시예고2026-07-23
Neutral투자판단관련주요경영사항(임상시험결과) (HIV-1 치료제 STP0404 임상 2a상 임상시험 탑라인 결과)2026-07-14